Frank C Lai, MD
Urology · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 29
- 6 carriers
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Hospitals listed: El Camino Health · Good Samaritan Hospital. That is not proof they admit you there this week.
Plans that list them
29 plans · 6 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lai’s office at (650) 962-4321 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
29 of 29 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A67706 · Current
Licensed to practise in California · since 1999 · expires 2028-08-31 · Northwestern University Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$748,409
Medicare paid this office $748,409 for 1,170 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 997 | $208,869 | $111 |
| Injection, testosterone undecanoate, 1 mg | 34 | $131,873 | None |
| Injection, denosumab, 1 mg | 12 | $53,387 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 163 | $46,077 | $240 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 90 | $33,510 | $368 |
See all 37 services
| Return visit (30+ min) | 997 | $208,869 | $111 |
| Injection, testosterone undecanoate, 1 mg | 34 | $131,873 | None |
| Injection, denosumab, 1 mg | 12 | $53,387 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 163 | $46,077 | $240 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 90 | $33,510 | $368 |
| Complete ultrasound scan behind abdominal cavity | 211 | $23,805 | $106 |
| New patient visit (45+ min) | 146 | $20,161 | $138 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 849 | $18,593 | $14 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 22 | $18,551 | None |
| Long return visit (40+ min) | 93 | $17,166 | $159 |
| Short return visit (20+ min) | 116 | $12,776 | $76 |
| Limited ultrasound scan of pelvis | 209 | $9,546 | $43 |
| Ultrasound scan of pelvic region through rectum | 60 | $8,828 | $136 |
| Insertion of lower leg neurostimulator electrode | 12 | $7,463 | $117 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 13 | $5,618 | $375 |
| Simple bladder irrigation and/or instillation | 57 | $5,288 | $78 |
| Ultrasound measurement of bladder capacity after voiding | 377 | $4,913 | $11 |
| Simple insertion of temporary bladder tube | 31 | $4,896 | $61 |
| New patient visit (60+ min) | 24 | $4,807 | $200 |
| Biopsy of prostate gland | 20 | $4,705 | $235 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 14 | $4,549 | $325 |
| Instillation of anti-cancer drug into bladder | 13 | $4,358 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $4,138 | $58 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,061 | $140 |
| Injection of drug or substance under skin or into muscle | 68 | $2,808 | $13 |
| Insertion of stent in ureter using an endoscope | 16 | $2,438 | $135 |
| Biopsy of prostate gland | 20 | $2,286 | $114 |
| Electronic assessment of bladder emptying | 175 | $1,678 | $9 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $1,274 | $42 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 22 | $1,213 | $35 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 19 | $670 | $24 |
| Ultrasound scan of pelvic region through rectum | 20 | $587 | $29 |
| Imaging of urinary tract following injection of a contrast agent | 23 | $552 | $21 |
| Ultrasonic guidance for needle placement | 17 | $453 | $27 |
| Urinalysis, manual test | 110 | $406 | $3 |
| Manual urinalysis test with examination using microscope, automated | 89 | $299 | $3 |
| Injection, ceftriaxone sodium, per 250 mg | 21 | $27 | None |
Procedures Medicare counted
| Prostate resection | 17 | More than 74% of doctors who do this |
Who their Medicare patients are
1,170 Original Medicare patients in 2024. Average age 78 · Under 65 1% · 85 and older 20% · Women 13% · Also on Medicaid 9% · Health risk score 1.17. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Cancer 36% · Coronary heart disease 34% · Diabetes 33% · Chronic kidney disease 26% · Atrial fibrillation 20% · Heart failure 14% · Depression 10% · COPD 9% · Dementia 7% · Stroke 7%.
The office billed $3,000,947, Medicare allowed $987,601 and paid $748,409; for 108,843 services of 105 kinds; $208,476 of it was for drugs given in the office and $539,933 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,170 | 108,843 | 78 | 1.17 | $3,000,947 | $748,409 |
| 2023 | 1,208 | 132,668 | 78 | 1.14 | $2,446,624 | $955,236 |
| 2022 | 1,208 | 132,197 | 77 | 1.15 | $2,633,245 | $1,060,902 |
| 2021 | 1,059 | 136,699 | 77 | 1.14 | $2,386,015 | $978,099 |
| 2020 | 914 | 106,475 | 77 | 1.21 | $1,948,577 | $736,508 |
| 2019 | 1,028 | 120,795 | 77 | 1.18 | $2,415,107 | $897,310 |
| 2018 | 992 | 94,984 | 77 | 1.18 | $2,542,852 | $1,024,897 |
| 2017 | 921 | 82,782 | 77 | 1.19 | $1,809,463 | $660,155 |
| 2016 | 864 | 88,164 | 77 | 1.24 | $1,720,581 | $607,101 |
| 2015 | 860 | 81,792 | 77 | 1.16 | $1,728,680 | $610,597 |
| 2014 | 818 | 12,396 | 77 | 1.18 | $1,385,281 | $501,855 |
| 2013 | 790 | 11,589 | 77 | 1.12 | $1,320,175 | $465,711 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 42 services
| Return visit (30+ min) | 1,046 | $225,654 | $108 |
| Injection, testosterone undecanoate, 1 mg | 39 | $155,887 | None |
| Injection, denosumab, 1 mg | 13 | $71,780 | None |
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 13 | $62,587 | $963 |
| Diagnostic exam of bladder and urethra using an endoscope | 204 | $55,797 | $231 |
| Complete ultrasound scan behind abdominal cavity | 267 | $33,815 | $108 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 77 | $30,716 | $384 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 23 | $25,485 | None |
| New patient visit (45+ min) | 164 | $23,126 | $141 |
| Short return visit (20+ min) | 148 | $20,118 | $80 |
| Insertion of lower leg neurostimulator electrode | 22 | $18,575 | $121 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 13 | $17,999 | $1,385 |
| Limited ultrasound scan of pelvis | 269 | $13,683 | $44 |
| Waterjet destruction of prostrate accessed through the urethra | 18 | $11,866 | $659 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 27 | $11,798 | $358 |
| Ultrasound scan of pelvic region through rectum | 68 | $9,999 | $143 |
| Long return visit (40+ min) | 51 | $8,575 | $162 |
| Ultrasound measurement of bladder capacity after voiding | 569 | $8,343 | $11 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $7,725 | $70 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 19 | $6,379 | $319 |
| Biopsy of prostate gland | 23 | $5,330 | $232 |
| Instillation of anti-cancer drug into bladder | 12 | $5,315 | $86 |
| Simple bladder irrigation and/or instillation | 57 | $5,245 | $77 |
| Electronic assessment of bladder emptying | 391 | $5,101 | $11 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,376 | $156 |
| Complicated insertion of bladder tube | 17 | $4,059 | $145 |
| Dilation of bladder and urethra using an endoscope | 19 | $4,037 | $168 |
| New patient visit (60+ min) | 19 | $3,594 | $189 |
| Injection of drug or substance under skin or into muscle | 79 | $3,555 | $14 |
| Manual urinalysis test with examination using microscope, automated | 669 | $2,942 | $3 |
| Insertion of stent in ureter using an endoscope | 17 | $2,102 | $100 |
| Simple insertion of temporary bladder tube | 20 | $2,085 | $63 |
| Biopsy of prostate gland | 18 | $1,943 | $108 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 26 | $1,907 | $66 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 24 | $1,607 | $33 |
| Destruction of tissue of bladder, urethra, or surrounding glands using an endoscope | 11 | $1,562 | $130 |
| Ultrasonic guidance for needle placement | 25 | $1,426 | $57 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 16 | $1,294 | $24 |
| Imaging of urinary tract following injection of a contrast agent | 43 | $1,173 | $22 |
| Ultrasound scan of pelvic region through rectum | 21 | $704 | $29 |
| Ultrasonic guidance for needle placement | 14 | $461 | $27 |
| Injection, ceftriaxone sodium, per 250 mg | 13 | $5 | None |
2022: 39 services
| Return visit (30+ min) | 1,033 | $238,451 | $110 |
| Injection, testosterone undecanoate, 1 mg | 41 | $144,987 | None |
| Injection, denosumab, 1 mg | 17 | $64,056 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 217 | $60,723 | $234 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 27 | $29,932 | None |
| Complete ultrasound scan behind abdominal cavity | 229 | $29,491 | $114 |
| New patient visit (45+ min) | 206 | $29,037 | $141 |
| Short return visit (20+ min) | 175 | $26,352 | $81 |
| Insertion of lower leg neurostimulator electrode | 19 | $22,505 | $124 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 52 | $21,401 | $396 |
| Complete ultrasound scan of pelvis | 179 | $20,711 | $105 |
| Complicated insertion of bladder tube | 36 | $17,176 | $152 |
| Ultrasound scan of pelvic region through rectum | 98 | $15,420 | $148 |
| Waterjet destruction of prostrate accessed through the urethra | 17 | $11,294 | $664 |
| Ultrasound measurement of bladder capacity after voiding | 588 | $8,827 | $11 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $7,518 | $175 |
| Long return visit (40+ min) | 46 | $7,329 | $159 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 18 | $7,160 | $377 |
| Biopsy of prostate gland | 30 | $6,400 | $213 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 19 | $6,306 | $332 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $5,205 | $64 |
| Electronic assessment of bladder emptying | 370 | $5,148 | $11 |
| Simple bladder irrigation and/or instillation | 54 | $4,656 | $79 |
| Instillation of anti-cancer drug into bladder | 12 | $3,705 | $88 |
| Injection of drug or substance under skin or into muscle | 101 | $3,605 | $13 |
| Manual urinalysis test with examination using microscope, automated | 719 | $3,492 | $3 |
| Limited ultrasound scan of pelvis | 55 | $2,673 | $49 |
| New patient visit (60+ min) | 12 | $2,276 | $190 |
| Ultrasonic guidance for needle placement | 33 | $1,877 | $57 |
| Destruction of tissue of bladder, urethra, or surrounding glands using an endoscope | 12 | $1,786 | $149 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 27 | $1,714 | $34 |
| Dilation of bladder and urethra using an endoscope | 11 | $1,692 | $154 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 15 | $1,678 | $23 |
| Biopsy of prostate gland | 15 | $1,517 | $101 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 19 | $1,313 | $66 |
| Imaging of urinary tract following injection of a contrast agent | 26 | $655 | $23 |
| Ultrasound scan of pelvic region through rectum | 18 | $544 | $29 |
| Ultrasonic guidance for needle placement | 17 | $448 | $26 |
| Injection, ceftriaxone sodium, per 250 mg | 32 | $13 | None |
2021: 39 services
| Return visit (30+ min) | 892 | $213,294 | $114 |
| Injection, testosterone undecanoate, 1 mg | 37 | $143,921 | None |
| Injection, denosumab, 1 mg | 22 | $82,333 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 207 | $53,840 | $218 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 88 | $35,046 | $398 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 29 | $34,184 | None |
| Insertion of lower leg neurostimulator electrode | 25 | $32,697 | $135 |
| Short return visit (20+ min) | 222 | $30,952 | $80 |
| New patient visit (45+ min) | 203 | $30,265 | $149 |
| Complete ultrasound scan behind abdominal cavity | 193 | $25,918 | $118 |
| Complete ultrasound scan of pelvis | 187 | $24,136 | $114 |
| Complicated insertion of bladder tube | 46 | $19,288 | $147 |
| Ultrasound scan of pelvic region through rectum | 96 | $14,357 | $144 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 22 | $9,504 | $339 |
| Ultrasound measurement of bladder capacity after voiding | 540 | $8,694 | $11 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 28 | $8,645 | $298 |
| Waterjet destruction of prostrate accessed through the urethra | 11 | $7,441 | $676 |
| Long return visit (40+ min) | 42 | $7,132 | $162 |
| Simple bladder irrigation and/or instillation | 48 | $5,142 | $79 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $5,109 | $170 |
| Electronic assessment of bladder emptying | 336 | $4,610 | $11 |
| Biopsy of prostate gland | 17 | $3,994 | $235 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $3,695 | $66 |
| Injection of drug or substance under skin or into muscle | 93 | $3,565 | $13 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 23 | $3,122 | $108 |
| Manual urinalysis test with examination using microscope, automated | 639 | $3,039 | $3 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 22 | $2,436 | $24 |
| New patient visit (60+ min) | 12 | $2,348 | $196 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 29 | $1,997 | $33 |
| Insertion of stent in ureter using an endoscope | 15 | $1,815 | $121 |
| Destruction of tissue of bladder, urethra, or surrounding glands using an endoscope | 11 | $1,675 | $152 |
| Biopsy of prostate gland | 11 | $1,234 | $112 |
| New patient visit (30+ min) | 12 | $1,227 | $102 |
| Ultrasonic guidance for needle placement | 16 | $882 | $55 |
| Imaging of urinary tract following injection of a contrast agent | 30 | $858 | $23 |
| Ultrasound scan of pelvic region through rectum | 12 | $369 | $31 |
| Ultrasonic guidance for needle placement | 12 | $341 | $28 |
| Injection, testosterone cypionate, 1 mg | 12 | $166 | None |
| Injection, ceftriaxone sodium, per 250 mg | 24 | $12 | None |
2020: 37 services
| Return visit (30+ min) | 721 | $136,248 | $95 |
| Injection, testosterone undecanoate, 1 mg | 30 | $105,741 | None |
| Injection, denosumab, 1 mg | 21 | $76,355 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 182 | $45,305 | $200 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 31 | $43,823 | None |
| Short return visit (20+ min) | 228 | $22,761 | $65 |
| New patient visit (45+ min) | 149 | $20,015 | $134 |
| Insertion of lower leg neurostimulator electrode | 21 | $19,167 | $131 |
| Complete ultrasound scan behind abdominal cavity | 138 | $17,337 | $116 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 46 | $16,836 | $366 |
| Complicated insertion of bladder tube | 40 | $15,950 | $135 |
| Complete ultrasound scan of pelvis | 123 | $14,213 | $107 |
| Ultrasound scan of pelvic region through rectum | 77 | $11,951 | $149 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 18 | $6,945 | $347 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $6,776 | $183 |
| Long return visit (40+ min) | 48 | $6,513 | $128 |
| Ultrasound measurement of bladder capacity after voiding | 407 | $6,085 | $10 |
| Biopsy of prostate gland | 21 | $4,826 | $230 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 15 | $4,187 | $279 |
| Electronic assessment of bladder emptying | 241 | $3,556 | $12 |
| Simple bladder irrigation and/or instillation | 33 | $3,539 | $75 |
| Injection of drug or substance under skin or into muscle | 94 | $3,031 | $13 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $2,590 | $62 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 24 | $2,492 | $24 |
| Manual urinalysis test with examination using microscope, automated | 534 | $2,438 | $3 |
| Biopsy of prostate gland | 19 | $2,172 | $114 |
| Insertion of stent in ureter using an endoscope | 16 | $2,082 | $122 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 31 | $2,008 | $31 |
| Ultrasound of abdomen and pelvis artery and vein blood flow | 11 | $1,860 | $155 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 18 | $1,732 | $82 |
| Telephone medical discussion with physician, 11-20 minutes | 26 | $1,730 | $67 |
| Ultrasonic guidance for needle placement | 21 | $1,200 | $57 |
| Ultrasound scan of pelvic region through rectum | 25 | $812 | $31 |
| Ultrasonic guidance for needle placement | 21 | $613 | $29 |
| Short return visit | 13 | $537 | $41 |
| Telephone medical discussion with physician, 5-10 minutes | 12 | $336 | $26 |
| Injection, ceftriaxone sodium, per 250 mg | 34 | $15 | None |
2019: 38 services
| Return visit (30+ min) | 805 | $155,060 | $95 |
| Injection, testosterone undecanoate, 1 mg | 34 | $103,803 | None |
| Injection, denosumab, 1 mg | 23 | $92,662 | None |
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 12 | $65,303 | $1,037 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 41 | $50,757 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 185 | $42,910 | $177 |
| Short return visit (20+ min) | 295 | $31,023 | $65 |
| New patient visit (45+ min) | 171 | $23,646 | $138 |
| Complicated insertion of bladder tube | 46 | $18,565 | $130 |
| Complete ultrasound scan behind abdominal cavity | 143 | $17,806 | $114 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 52 | $17,558 | $331 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 12 | $16,209 | $1,351 |
| Complete ultrasound scan of pelvis | 138 | $15,957 | $109 |
| Surgical removal of prostate and surrounding lymph nodes using an endoscope | 12 | $15,011 | $1,251 |
| Ultrasound scan of pelvic region through rectum | 96 | $13,806 | $130 |
| Ultrasound measurement of bladder capacity after voiding | 493 | $9,225 | $13 |
| Biopsy of prostate gland | 34 | $8,438 | $248 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 17 | $7,592 | $380 |
| Long return visit (40+ min) | 54 | $7,038 | $128 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 18 | $5,136 | $285 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 18 | $4,797 | $266 |
| New patient visit (60+ min) | 24 | $4,317 | $180 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,060 | $177 |
| Injection of drug or substance under skin or into muscle | 95 | $4,053 | $16 |
| Electronic assessment of bladder emptying | 271 | $3,978 | $11 |
| Manual urinalysis test with examination using microscope, automated | 684 | $3,750 | $3 |
| Simple bladder irrigation and/or instillation | 40 | $3,654 | $72 |
| Removal of lymph nodes of both sides of pelvis using an endoscope | 11 | $3,240 | $295 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $2,434 | $66 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $2,383 | $82 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 42 | $2,262 | $31 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 17 | $2,088 | $95 |
| Ultrasonic guidance for needle placement | 34 | $1,937 | $54 |
| Biopsy of prostate gland | 11 | $1,309 | $119 |
| Ultrasound scan of pelvic region through rectum | 14 | $463 | $31 |
| Ultrasonic guidance for needle placement | 14 | $438 | $29 |
| Injection, testosterone cypionate, 1 mg | 15 | $206 | None |
| Injection, ceftriaxone sodium, per 250 mg | 37 | $16 | None |
2018: 35 services
| Return visit (30+ min) | 634 | $112,125 | $93 |
| Injection, denosumab, 1 mg | 18 | $96,283 | None |
| Injection, testosterone undecanoate, 1 mg | 31 | $85,372 | None |
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 12 | $53,713 | $1,033 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 33 | $47,569 | None |
| Short return visit (20+ min) | 438 | $43,576 | $63 |
| Diagnostic exam of bladder and urethra using an endoscope | 180 | $35,076 | $161 |
| New patient visit (45+ min) | 152 | $20,428 | $134 |
| Complicated insertion of bladder tube | 41 | $17,535 | $122 |
| Complete ultrasound scan behind abdominal cavity | 129 | $16,744 | $115 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 12 | $15,827 | $1,319 |
| Complete ultrasound scan of pelvis | 125 | $15,249 | $109 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 24 | $10,163 | $376 |
| Long return visit (40+ min) | 70 | $10,129 | $133 |
| Ultrasound measurement of bladder capacity after voiding | 472 | $10,127 | $16 |
| Ultrasound scan of pelvic region through rectum | 74 | $7,623 | $99 |
| Biopsy of prostate gland | 32 | $7,547 | $236 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $6,406 | $178 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 26 | $6,165 | $237 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 16 | $4,895 | $288 |
| New patient visit (60+ min) | 24 | $4,348 | $181 |
| Manual urinalysis test with examination using microscope, automated | 700 | $4,333 | $4 |
| Electronic assessment of bladder emptying | 261 | $4,145 | $13 |
| Injection of drug or substance under skin or into muscle | 88 | $3,843 | $19 |
| Simple bladder irrigation and/or instillation | 39 | $3,683 | $74 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $2,681 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $2,549 | $65 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 26 | $2,409 | $83 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 36 | $2,113 | $30 |
| Ultrasonic guidance for needle placement | 34 | $2,056 | $59 |
| New patient visit (30+ min) | 18 | $1,622 | $90 |
| Insertion of stent in ureter using an endoscope | 15 | $1,572 | $105 |
| Imaging of urinary tract following injection of a contrast agent | 20 | $354 | $16 |
| Ultrasound scan of pelvic region through rectum | 11 | $340 | $31 |
| Injection, ceftriaxone sodium, per 250 mg | 37 | $18 | None |
2017: 32 services
| Return visit (30+ min) | 570 | $91,806 | $90 |
| Injection, testosterone undecanoate, 1 mg | 24 | $74,805 | None |
| Injection, denosumab, 1 mg | 17 | $72,311 | None |
| Short return visit (20+ min) | 455 | $45,292 | $63 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 29 | $36,096 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 153 | $30,153 | $159 |
| Destruction of prostate tissue using radiofrequency induced heat | 12 | $23,457 | $1,955 |
| New patient visit (45+ min) | 129 | $17,414 | $135 |
| Complicated insertion of bladder tube | 46 | $15,743 | $117 |
| Ultrasound measurement of bladder capacity after voiding | 524 | $13,771 | $19 |
| Complete ultrasound scan behind abdominal cavity | 114 | $13,680 | $113 |
| Complete ultrasound scan of pelvis | 110 | $12,525 | $108 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 24 | $9,534 | $353 |
| Long return visit (40+ min) | 61 | $8,535 | $129 |
| Ultrasound scan of pelvic region through rectum | 74 | $7,808 | $93 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 26 | $7,539 | $290 |
| Biopsy of prostate gland | 31 | $7,281 | $235 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 21 | $5,141 | $234 |
| Manual urinalysis test with examination using microscope, automated | 693 | $4,702 | $4 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,572 | $176 |
| Injection of drug or substance under skin or into muscle | 55 | $4,382 | $25 |
| New patient visit (30+ min) | 45 | $4,238 | $94 |
| Electronic assessment of bladder emptying | 272 | $3,910 | $13 |
| Simple bladder irrigation and/or instillation | 38 | $3,486 | $71 |
| Insertion of stent in ureter using an endoscope | 17 | $2,295 | $115 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 25 | $2,151 | $72 |
| Ultrasonic guidance for needle placement | 33 | $2,058 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,901 | $63 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 29 | $1,453 | $30 |
| Imaging of urinary tract following injection of a contrast agent | 17 | $327 | $16 |
| Ultrasonic guidance for needle placement | 11 | $321 | $29 |
| Injection, testosterone cypionate, 1 mg | 11 | $69 | None |
2016: 38 services
| Return visit (30+ min) | 580 | $93,981 | $86 |
| Injection, denosumab, 1 mg | 15 | $81,731 | None |
| Injection, testosterone undecanoate, 1 mg | 28 | $65,584 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 26 | $38,157 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 156 | $37,017 | $185 |
| Short return visit (20+ min) | 370 | $33,000 | $58 |
| New patient visit (45+ min) | 117 | $15,029 | $128 |
| Complete ultrasound scan behind abdominal cavity | 108 | $12,818 | $107 |
| Complicated insertion of bladder tube | 31 | $12,152 | $111 |
| Unclassified drugs | 11 | $11,972 | None |
| Ultrasound measurement of bladder capacity after voiding | 459 | $11,147 | $17 |
| Long return visit (40+ min) | 70 | $9,272 | $119 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 19 | $7,401 | $322 |
| Biopsy of prostate gland | 34 | $6,201 | $182 |
| Ultrasound scan of pelvic region through rectum | 62 | $5,924 | $88 |
| Complete ultrasound scan of pelvis | 51 | $5,546 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $5,540 | $173 |
| Manual urinalysis test with examination using microscope, automated | 686 | $5,234 | $4 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 18 | $4,211 | $222 |
| Injection of drug or substance under skin or into muscle | 54 | $4,178 | $22 |
| New patient visit (60+ min) | 19 | $3,329 | $175 |
| Electronic assessment of bladder emptying | 241 | $3,315 | $12 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 18 | $2,904 | $126 |
| Simple bladder irrigation and/or instillation | 32 | $2,613 | $75 |
| Placement of hormone pellet under skin | 11 | $2,344 | $81 |
| Screening test for pathogenic organisms | 179 | $2,159 | $9 |
| Ultrasound of abdomen and pelvis artery and vein blood flow | 14 | $2,105 | $150 |
| Ultrasonic guidance for needle placement | 35 | $1,981 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,853 | $60 |
| New patient visit (30+ min) | 20 | $1,838 | $92 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 56 | $1,583 | $18 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 26 | $1,125 | $27 |
| Bacterial colony count, urine | 58 | $787 | $11 |
| Evaluation of antimicrobial drug (antibiotic, antifungal, antiviral) | 58 | $672 | $9 |
| Bacterial urine culture | 58 | $639 | $9 |
| Immunologic analysis for detection of tumor antigen, qualitative or semiquantitative | 22 | $632 | $25 |
| Ultrasound scan of pelvic region through rectum | 11 | $321 | $29 |
| Injection, testosterone cypionate, 1 mg | 16 | $90 | None |
2015: 40 services
| Return visit (30+ min) | 558 | $88,627 | $91 |
| Injection, denosumab, 1 mg | 20 | $73,871 | None |
| Injection, testosterone undecanoate, 1 mg | 25 | $55,071 | None |
| Short return visit (20+ min) | 427 | $43,030 | $62 |
| Diagnostic exam of bladder and urethra using an endoscope | 164 | $38,193 | $194 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 24 | $36,072 | None |
| New patient visit (45+ min) | 114 | $16,157 | $142 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 32 | $15,883 | $496 |
| Complete ultrasound scan behind abdominal cavity | 105 | $12,817 | $111 |
| Ultrasound measurement of bladder capacity after voiding | 449 | $12,657 | $19 |
| Complicated insertion of bladder tube | 36 | $8,329 | $124 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 11 | $8,270 | $752 |
| Biopsy of prostate gland | 37 | $7,358 | $199 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $7,003 | $167 |
| Long return visit (40+ min) | 49 | $6,636 | $130 |
| Ultrasound scan of pelvic region through rectum | 66 | $6,307 | $93 |
| Manual urinalysis test with examination using microscope, automated | 709 | $5,778 | $4 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 13 | $5,714 | $336 |
| Injection of drug or substance under skin or into muscle | 63 | $4,985 | $24 |
| Ultrasound of abdomen and pelvis artery and vein blood flow | 29 | $4,912 | $158 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $4,531 | $65 |
| Electronic assessment of bladder emptying | 221 | $3,588 | $13 |
| Simple bladder irrigation and/or instillation | 44 | $3,480 | $74 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 13 | $3,058 | $218 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 85 | $2,841 | $18 |
| Screening test for pathogenic organisms | 220 | $2,768 | $9 |
| New patient visit (30+ min) | 30 | $2,431 | $81 |
| Ultrasonic guidance for needle placement | 37 | $2,211 | $57 |
| Immunologic analysis for detection of tumor antigen, qualitative or semiquantitative | 62 | $1,989 | $26 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 14 | $1,518 | $84 |
| Bacterial colony count, urine | 73 | $1,282 | $11 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 22 | $1,206 | $33 |
| Destruction of tissue of bladder, urethra, or surrounding glands using an endoscope | 11 | $1,186 | $91 |
| Evaluation of antimicrobial drug (antibiotic, antifungal, antiviral) | 71 | $1,076 | $9 |
| Bacterial urine culture | 73 | $1,040 | $9 |
| Short return visit | 12 | $462 | $39 |
| Ultrasound scan of pelvic region through rectum | 15 | $456 | $30 |
| Ultrasonic guidance for needle placement | 11 | $296 | $27 |
| Biopsy of bladder using an endoscope | 14 | $192 | $12 |
| Injection, testosterone cypionate, 1 mg | 19 | $149 | None |
2014: 39 services
| Return visit (30+ min) | 496 | $80,907 | $92 |
| Unclassified drugs | 33 | $45,596 | None |
| Short return visit (20+ min) | 419 | $44,596 | $62 |
| Injection, denosumab, 1 mg | 14 | $41,157 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 148 | $34,265 | $178 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 21 | $30,282 | None |
| New patient visit (45+ min) | 118 | $16,424 | $139 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 17 | $12,880 | $758 |
| Complete ultrasound scan behind abdominal cavity | 75 | $11,173 | $131 |
| Ultrasound measurement of bladder capacity after voiding | 399 | $10,951 | $19 |
| Complicated insertion of bladder tube | 36 | $10,056 | $118 |
| Long return visit (40+ min) | 50 | $6,800 | $133 |
| Biopsy of prostate gland | 33 | $6,436 | $195 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $5,936 | $180 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 13 | $5,827 | $364 |
| Manual urinalysis test with examination using microscope, automated | 617 | $4,937 | $4 |
| Ultrasound scan of pelvic region through rectum | 54 | $4,919 | $89 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 21 | $4,784 | $228 |
| Injection of drug or substance under skin or into muscle | 68 | $4,646 | $23 |
| New patient visit (60+ min) | 19 | $3,580 | $188 |
| Ultrasound of abdomen and pelvis artery and vein blood flow | 17 | $3,401 | $200 |
| Simple bladder irrigation and/or instillation | 42 | $3,229 | $67 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 16 | $3,190 | $152 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $2,690 | $63 |
| Electronic assessment of bladder emptying | 171 | $2,597 | $13 |
| Ultrasonic guidance for needle placement | 33 | $2,394 | $68 |
| Placement of hormone pellet under skin | 16 | $2,394 | $92 |
| Screening test for pathogenic organisms | 194 | $2,378 | $9 |
| Insertion of stent in ureter using an endoscope | 18 | $2,156 | $94 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 74 | $2,050 | $17 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 23 | $1,373 | $32 |
| Simple repair of surface wound of scalp, neck, underarms, trunk, arms, or legs, 2.5 cm or less | 16 | $1,114 | $43 |
| Bacterial colony count, urine | 65 | $1,047 | $11 |
| Evaluation of antimicrobial drug (antibiotic, antifungal, antiviral) | 65 | $885 | $9 |
| Bacterial urine culture | 65 | $850 | $9 |
| Limited ultrasound scan behind abdominal cavity | 14 | $741 | $53 |
| Immunologic analysis for detection of tumor antigen, qualitative or semiquantitative | 23 | $649 | $26 |
| Short return visit | 17 | $623 | $37 |
| Injection, testosterone cypionate, 1 cc, 200 mg | 38 | $319 | None |
2013: 42 services
| Return visit (30+ min) | 561 | $90,037 | $89 |
| Injection, denosumab, 1 mg | 13 | $39,334 | None |
| Short return visit (20+ min) | 300 | $33,238 | $65 |
| Diagnostic exam of bladder and urethra using an endoscope | 136 | $31,344 | $184 |
| Unclassified drugs | 25 | $21,352 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 13 | $16,771 | None |
| Complicated insertion of bladder tube | 39 | $12,723 | $121 |
| Ultrasound measurement of bladder capacity after voiding | 422 | $12,040 | $19 |
| New patient visit (45+ min) | 86 | $11,716 | $136 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 15 | $11,062 | $737 |
| Long return visit (40+ min) | 57 | $8,514 | $131 |
| Ultrasonic guidance for needle placement | 33 | $7,277 | $208 |
| Complete ultrasound scan behind abdominal cavity | 47 | $6,172 | $129 |
| Biopsy of prostate gland | 31 | $6,118 | $197 |
| Manual urinalysis test with examination using microscope, automated | 624 | $5,134 | $4 |
| Crushing of stone of ureter using an endoscope | 12 | $4,560 | $326 |
| Complicated change of bladder tube | 12 | $4,481 | $76 |
| Injection of drug or substance under skin or into muscle | 73 | $4,480 | $24 |
| Placement of hormone pellet under skin | 24 | $4,038 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $3,992 | $166 |
| New patient visit (60+ min) | 21 | $3,731 | $178 |
| Dilation of urethra using an endoscope | 13 | $3,622 | $241 |
| Irrigation and removal of multiple blood clots from bladder and urethra using an endoscope | 11 | $3,290 | $274 |
| Limited ultrasound scan behind abdominal cavity | 29 | $3,246 | $108 |
| Ultrasound scan of pelvic region through rectum | 47 | $3,221 | $69 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 12 | $2,960 | $228 |
| Electronic assessment of bladder emptying | 206 | $2,915 | $12 |
| Screening test for pathogenic organisms | 225 | $2,869 | $9 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 102 | $2,818 | $18 |
| Simple bladder irrigation and/or instillation | 35 | $2,767 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $2,377 | $61 |
| Insertion of stent in ureter using an endoscope | 22 | $2,368 | $74 |
| Simple repair of surface wound of scalp, neck, underarms, trunk, arms, or legs, 2.5 cm or less | 25 | $2,036 | $45 |
| Removal or manipulation of stone in ureter or kidney using an endoscope | 15 | $1,843 | $108 |
| Short return visit | 25 | $1,173 | $40 |
| Bacterial colony count, urine | 66 | $1,159 | $11 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $983 | $32 |
| Evaluation of antimicrobial drug (antibiotic, antifungal, antiviral) | 65 | $982 | $9 |
| Bacterial urine culture | 66 | $941 | $9 |
| Cell examination of specimen, selective cellular enhancement technique | 12 | $751 | $54 |
| Injection, testosterone cypionate, 1 cc, 200 mg | 51 | $586 | None |
| Immunologic analysis for detection of tumor antigen, qualitative or semiquantitative | 19 | $533 | $27 |
Medicaid work
$75 in 2024
Medicaid paid $75 for 111 billed services this clinician did in 2024, up to 18 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 111 | $75 |
| 2024 | 111 | 1 | 18 | $75 |
| 2023 | 379 | 4 | 37 | $571 |
| 2022 | 526 | 3 | 31 | $669 |
| 2021 | 494 | 3 | 29 | $597 |
| 2020 | 412 | 3 | 29 | $748 |
| 2019 | 823 | 4 | 34 | $675 |
| 2018 | 347 | 5 | 24 | $156 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 246 | $441 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 42 | $124 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 79 | $6 |
| New patient visit (45+ min) | 12 | $0 |
2022
| Return visit (30+ min) | 286 | $482 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 86 | $183 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 154 | $5 |
2021
| Return visit (30+ min) | 266 | $506 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 55 | $78 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 173 | $13 |
2020
| Return visit (30+ min) | 230 | $475 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 28 | $260 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 154 | $13 |
2019
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 148 | $425 |
| Return visit (30+ min) | 312 | $203 |
| New patient visit (45+ min) | 59 | $43 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 304 | $5 |
2018
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 44 | $123 |
| Short return visit (20+ min) | 27 | $25 |
| Return visit (30+ min) | 79 | $5 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 184 | $3 |
| New patient visit (45+ min) | 13 | $0 |
Drugs they prescribed that Part D paid
$438,829
Pharmacies billed $438,829 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
2,676 generic and 155 brand-name prescriptions · $438,829 in drug cost · 349 antibiotic prescriptions to 216 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 22 | $242,520 | $11,024 |
| Gemtesa | 52 | $72,233 | $1,389 |
| Myrbetriq | 59 | $48,165 | $816 |
| Tamsulosin | 862 | $14,385 | $17 |
| Finasteride | 704 | $11,254 | $16 |
See all 29 drugs
| Xtandi | 22 | $242,520 | $11,024 |
| Gemtesa | 52 | $72,233 | $1,389 |
| Myrbetriq | 59 | $48,165 | $816 |
| Tamsulosin | 862 | $14,385 | $17 |
| Finasteride | 704 | $11,254 | $16 |
| Potassium Citrate Er | 65 | $10,783 | $166 |
| Alfuzosin Hcl Er | 177 | $4,526 | $26 |
| Dutasteride | 82 | $3,608 | $44 |
| Testosterone | 26 | $3,520 | $135 |
| Silodosin | 44 | $3,052 | $69 |
| Tadalafil | 31 | $2,530 | $82 |
| Testosterone Cypionate | 22 | $1,463 | $66 |
| Solifenacin | 13 | $1,129 | $87 |
| Oxybutynin Chloride Er | 24 | $898 | $37 |
| Estradiol | 13 | $714 | $55 |
| Doxazosin Mesylate | 45 | $546 | $12 |
| Trospium Chloride | 14 | $530 | $38 |
| Cephalexin | 141 | $530 | $4 |
| Sildenafil Citrate | 44 | $419 | $10 |
| Bicalutamide | 17 | $418 | $25 |
| Chlorthalidone | 18 | $339 | $19 |
| Ciprofloxacin | 54 | $264 | $5 |
| Nitrofurantoin Mono-Macro | 24 | $259 | $11 |
| Amoxicillin-Clavulanate Potass | 31 | $188 | $6 |
| Terazosin | 20 | $161 | $8 |
| Levofloxacin | 43 | $124 | $3 |
| Allopurinol | 15 | $103 | $7 |
| Ibuprofen | 29 | $80 | $3 |
| Sulfamethoxazole-Trimethoprim | 33 | $55 | $2 |
Year by year
| 2024 | 2,831 | 755 | None | 5% | $438,829 |
| 2023 | 2,659 | 680 | 1% (19) | None | $370,374 |
| 2022 | 2,236 | 626 | 1% (15) | None | $180,124 |
| 2021 | 2,158 | 560 | 1% (31) | None | $240,921 |
| 2020 | 2,040 | 535 | 2% (37) | 5% | $183,324 |
| 2019 | 1,769 | 473 | 1% (20) | None | $116,698 |
| 2018 | 1,908 | 466 | 3% (51) | None | $236,629 |
| 2017 | 1,865 | 430 | 3% (57) | None | $142,327 |
| 2016 | 1,831 | 408 | 2% (37) | 9% | $177,279 |
| 2015 | 1,735 | 393 | 3% (47) | 10% | $140,383 |
| 2014 | 1,445 | 333 | 2% (34) | None | $85,578 |
| 2013 | 1,275 | 278 | 2% (29) | None | $77,208 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 27 drugs
| Xtandi | 15 | $204,248 | $13,617 |
| Gemtesa | 46 | $46,891 | $1,019 |
| Myrbetriq | 31 | $41,866 | $1,351 |
| Tamsulosin | 840 | $20,785 | $25 |
| Finasteride | 626 | $12,553 | $20 |
| Potassium Citrate Er | 60 | $11,627 | $194 |
| Alfuzosin Hcl Er | 210 | $6,343 | $30 |
| Dutasteride | 69 | $5,687 | $82 |
| Tadalafil | 43 | $2,702 | $63 |
| Silodosin | 23 | $2,330 | $101 |
| Oxybutynin Chloride Er | 34 | $1,703 | $50 |
| Bicalutamide | 23 | $1,145 | $50 |
| Cephalexin | 140 | $1,142 | $8 |
| Doxazosin Mesylate | 36 | $867 | $24 |
| Testosterone | 13 | $815 | $63 |
| Testosterone Cypionate | 13 | $715 | $55 |
| Nitrofurantoin Mono-Macro | 31 | $683 | $22 |
| Terazosin | 15 | $515 | $34 |
| Ciprofloxacin | 64 | $480 | $8 |
| Sildenafil Citrate | 24 | $409 | $17 |
| Chlorthalidone | 21 | $337 | $16 |
| Amoxicillin-Clavulanate Potass | 37 | $268 | $7 |
| Sulfamethoxazole-Trimethoprim | 40 | $167 | $4 |
| Ibuprofen | 35 | $165 | $5 |
| Levofloxacin | 26 | $100 | $4 |
| Allopurinol | 17 | $95 | $6 |
| Oxycodone-Acetaminophen | 12 | $57 | $5 |
2022: 22 drugs
| Myrbetriq | 39 | $45,633 | $1,170 |
| Tamsulosin | 710 | $15,524 | $22 |
| Gemtesa | 16 | $13,119 | $820 |
| Potassium Citrate Er | 60 | $11,349 | $189 |
| Finasteride | 490 | $10,365 | $21 |
| Alfuzosin Hcl Er | 177 | $5,769 | $33 |
| Dutasteride | 51 | $5,080 | $100 |
| Oxybutynin Chloride Er | 66 | $3,218 | $49 |
| Silodosin | 16 | $2,551 | $159 |
| Tadalafil | 31 | $2,298 | $74 |
| Testosterone Cypionate | 14 | $1,133 | $81 |
| Doxazosin Mesylate | 42 | $1,098 | $26 |
| Bicalutamide | 24 | $901 | $38 |
| Ciprofloxacin | 106 | $669 | $6 |
| Cephalexin | 130 | $657 | $5 |
| Chlorthalidone | 14 | $419 | $30 |
| Allopurinol | 11 | $269 | $24 |
| Amoxicillin-Clavulanate Potass | 27 | $252 | $9 |
| Nitrofurantoin Mono-Macro | 14 | $234 | $17 |
| Sulfamethoxazole-Trimethoprim | 21 | $90 | $4 |
| Ibuprofen | 21 | $86 | $4 |
| Levofloxacin | 12 | $41 | $3 |
2021: 24 drugs
| Xtandi | 14 | $130,842 | $9,346 |
| Myrbetriq | 36 | $35,241 | $979 |
| Tamsulosin | 696 | $15,013 | $22 |
| Potassium Citrate Er | 66 | $13,598 | $206 |
| Finasteride | 454 | $13,389 | $29 |
| Alfuzosin Hcl Er | 171 | $6,195 | $36 |
| Oxybutynin Chloride Er | 101 | $4,897 | $48 |
| Dutasteride | 22 | $2,381 | $108 |
| Silodosin | 17 | $2,258 | $133 |
| Testosterone | 13 | $1,774 | $136 |
| Tadalafil | 23 | $1,575 | $68 |
| Doxazosin Mesylate | 46 | $1,234 | $27 |
| Bicalutamide | 17 | $857 | $50 |
| Chlorthalidone | 18 | $839 | $47 |
| Cephalexin | 125 | $712 | $6 |
| Nitrofurantoin Mono-Macro | 21 | $402 | $19 |
| Ciprofloxacin | 63 | $350 | $6 |
| Terazosin | 11 | $335 | $30 |
| Hydrocodone-Acetaminophen | 27 | $293 | $11 |
| Allopurinol | 12 | $250 | $21 |
| Amoxicillin-Clavulanate Potass | 26 | $203 | $8 |
| Sulfamethoxazole-Trimethoprim | 33 | $130 | $4 |
| Levofloxacin | 13 | $77 | $6 |
| Ibuprofen | 17 | $64 | $4 |
2020: 20 drugs
| Myrbetriq | 41 | $39,205 | $956 |
| Potassium Citrate Er | 85 | $19,494 | $229 |
| Tamsulosin | 577 | $11,197 | $19 |
| Finasteride | 434 | $11,095 | $26 |
| Alfuzosin Hcl Er | 191 | $7,424 | $39 |
| Oxybutynin Chloride Er | 116 | $6,837 | $59 |
| Testosterone | 22 | $3,690 | $168 |
| Silodosin | 17 | $2,882 | $170 |
| Dutasteride | 12 | $1,445 | $120 |
| Chlorthalidone | 30 | $1,320 | $44 |
| Doxazosin Mesylate | 37 | $1,316 | $36 |
| Bicalutamide | 30 | $1,228 | $41 |
| Tadalafil | 14 | $662 | $47 |
| Cephalexin | 118 | $531 | $4 |
| Terazosin | 16 | $385 | $24 |
| Ciprofloxacin | 60 | $332 | $6 |
| Hydrocodone-Acetaminophen | 34 | $233 | $7 |
| Amoxicillin-Clavulanate Potass | 22 | $176 | $8 |
| Levofloxacin | 24 | $131 | $5 |
| Sulfamethoxazole-Trimethoprim | 21 | $69 | $3 |
2019: 20 drugs
| Myrbetriq | 25 | $21,598 | $864 |
| Potassium Citrate Er | 86 | $19,281 | $224 |
| Finasteride | 421 | $12,507 | $30 |
| Tamsulosin | 469 | $10,883 | $23 |
| Oxybutynin Chloride Er | 133 | $8,139 | $61 |
| Alfuzosin Hcl Er | 177 | $5,975 | $34 |
| Testosterone | 12 | $4,849 | $404 |
| Tadalafil | 11 | $3,448 | $313 |
| Silodosin | 15 | $3,269 | $218 |
| Renacidin | 11 | $2,753 | $250 |
| Potassium Chloride | 11 | $1,768 | $161 |
| Chlorthalidone | 28 | $1,410 | $50 |
| Doxazosin Mesylate | 42 | $1,333 | $32 |
| Terazosin | 23 | $594 | $26 |
| Bicalutamide | 19 | $410 | $22 |
| Nitrofurantoin Mono-Macro | 16 | $346 | $22 |
| Cephalexin | 80 | $334 | $4 |
| Ciprofloxacin | 41 | $258 | $6 |
| Hydrocodone-Acetaminophen | 18 | $167 | $9 |
| Sulfamethoxazole-Trimethoprim | 16 | $60 | $4 |
2018: 20 drugs
| Potassium Citrate Er | 66 | $16,384 | $248 |
| Myrbetriq | 28 | $14,988 | $535 |
| Tamsulosin | 460 | $12,114 | $26 |
| Finasteride | 478 | $11,879 | $25 |
| Rapaflo | 16 | $9,077 | $567 |
| Vesicare | 14 | $8,974 | $641 |
| Cialis | 18 | $8,045 | $447 |
| Oxybutynin Chloride Er | 120 | $7,496 | $62 |
| Alfuzosin Hcl Er | 209 | $5,799 | $28 |
| Renacidin | 18 | $3,716 | $206 |
| Chlorthalidone | 27 | $1,490 | $55 |
| Doxazosin Mesylate | 40 | $1,163 | $29 |
| Ciprofloxacin | 86 | $738 | $9 |
| Gabapentin | 12 | $674 | $56 |
| Testosterone Cypionate | 21 | $509 | $24 |
| Hydrocodone-Acetaminophen | 45 | $498 | $11 |
| Cephalexin | 55 | $330 | $6 |
| Terazosin | 22 | $314 | $14 |
| Sulfamethoxazole-Trimethoprim | 20 | $96 | $5 |
| Levofloxacin | 11 | $24 | $2 |
2017: 20 drugs
| Potassium Citrate Er | 69 | $16,808 | $244 |
| Tamsulosin | 468 | $16,186 | $35 |
| Finasteride | 495 | $12,702 | $26 |
| Myrbetriq | 19 | $11,816 | $622 |
| Cialis | 29 | $10,676 | $368 |
| Vesicare | 17 | $8,698 | $512 |
| Oxybutynin Chloride Er | 93 | $7,053 | $76 |
| Alfuzosin Hcl Er | 125 | $4,476 | $36 |
| Renacidin | 11 | $2,565 | $233 |
| Chlorthalidone | 35 | $1,632 | $47 |
| Doxazosin Mesylate | 43 | $1,319 | $31 |
| Potassium Chloride | 23 | $974 | $42 |
| Bicalutamide | 34 | $880 | $26 |
| Ciprofloxacin | 99 | $660 | $7 |
| Hydrocodone-Acetaminophen | 54 | $575 | $11 |
| Testosterone Cypionate | 12 | $325 | $27 |
| Terazosin | 22 | $300 | $14 |
| Nitrofurantoin Mono-Macro | 12 | $290 | $24 |
| Cephalexin | 41 | $163 | $4 |
| Sulfamethoxazole-Trimethoprim | 28 | $108 | $4 |
2016: 19 drugs
| Tamsulosin | 447 | $16,616 | $37 |
| Potassium Citrate Er | 58 | $14,710 | $254 |
| Finasteride | 488 | $13,649 | $28 |
| Vesicare | 21 | $10,407 | $496 |
| Myrbetriq | 27 | $9,220 | $341 |
| Cialis | 21 | $5,456 | $260 |
| Oxybutynin Chloride Er | 76 | $4,594 | $60 |
| Alfuzosin Hcl Er | 146 | $3,823 | $26 |
| Chlorthalidone | 49 | $1,915 | $39 |
| Doxazosin Mesylate | 40 | $1,361 | $34 |
| Potassium Chloride | 25 | $1,008 | $40 |
| Ciprofloxacin | 113 | $740 | $7 |
| Nitrofurantoin Mono-Macro | 23 | $516 | $22 |
| Hydrocodone-Acetaminophen | 33 | $503 | $15 |
| Bicalutamide | 27 | $439 | $16 |
| Terazosin | 27 | $355 | $13 |
| Cephalexin | 22 | $120 | $5 |
| Sulfamethoxazole-Trimethoprim | 22 | $87 | $4 |
| Hydrochlorothiazide | 12 | $39 | $3 |
2015: 23 drugs
| Tamsulosin | 424 | $18,078 | $43 |
| Potassium Citrate Er | 59 | $12,646 | $214 |
| Finasteride | 459 | $10,275 | $22 |
| Vesicare | 19 | $7,213 | $380 |
| Myrbetriq | 19 | $6,346 | $334 |
| Rapaflo | 14 | $5,039 | $360 |
| Cialis | 18 | $3,689 | $205 |
| Oxybutynin Chloride Er | 49 | $3,490 | $71 |
| Alfuzosin Hcl Er | 160 | $3,350 | $21 |
| Avodart | 15 | $2,406 | $160 |
| Doxazosin Mesylate | 39 | $1,954 | $50 |
| Chlorthalidone | 55 | $1,833 | $33 |
| Potassium Chloride | 29 | $1,178 | $41 |
| Hydrocodone-Acetaminophen | 43 | $534 | $12 |
| Terazosin | 27 | $493 | $18 |
| Ciprofloxacin | 84 | $397 | $5 |
| Bicalutamide | 11 | $323 | $29 |
| Nitrofurantoin Mono-Macro | 12 | $237 | $20 |
| Imipramine | 12 | $224 | $19 |
| Sulfamethoxazole-Trimethoprim | 27 | $120 | $4 |
| Levofloxacin | 12 | $104 | $9 |
| Sodium Chloride | 21 | $100 | $5 |
| Hydrochlorothiazide | 11 | $38 | $3 |
2014: 19 drugs
| Tamsulosin | 420 | $11,653 | $28 |
| Potassium Citrate Er | 48 | $9,796 | $204 |
| Finasteride | 393 | $9,370 | $24 |
| Vesicare | 23 | $8,821 | $384 |
| Androgel | 14 | $7,273 | $519 |
| Avodart | 14 | $5,740 | $410 |
| Oxytrol | 11 | $3,878 | $353 |
| Oxybutynin Chloride Er | 41 | $3,702 | $90 |
| Urocit-K | 20 | $3,643 | $182 |
| Alfuzosin Hcl Er | 75 | $2,347 | $31 |
| Doxazosin Mesylate | 42 | $2,019 | $48 |
| Chlorthalidone | 44 | $958 | $22 |
| Potassium Chloride | 20 | $742 | $37 |
| Ciprofloxacin | 72 | $441 | $6 |
| Terazosin | 20 | $409 | $20 |
| Hydrocodone-Acetaminophen | 29 | $405 | $14 |
| Nitrofurantoin Mono-Macro | 12 | $344 | $29 |
| Levofloxacin | 22 | $219 | $10 |
| Sulfamethoxazole-Trimethoprim | 13 | $63 | $5 |
2013: 19 drugs
| Finasteride | 383 | $11,885 | $31 |
| Tamsulosin | 344 | $9,750 | $28 |
| Vesicare | 21 | $8,464 | $403 |
| Potassium Citrate | 29 | $5,137 | $177 |
| Androgel | 13 | $5,065 | $390 |
| Avodart | 17 | $4,392 | $258 |
| Alfuzosin | 34 | $2,679 | $79 |
| Urocit-K | 20 | $2,610 | $131 |
| Oxybutynin Chloride Er | 26 | $2,595 | $100 |
| Trospium Chloride | 14 | $1,638 | $117 |
| Doxazosin Mesylate | 44 | $1,073 | $24 |
| Chlorthalidone | 41 | $695 | $17 |
| Hydrocodone-Acetaminophen | 18 | $637 | $35 |
| Potassium Chloride | 12 | $578 | $48 |
| Terazosin | 16 | $567 | $35 |
| Nitrofurantoin Mono-Macro | 16 | $522 | $33 |
| Oxybutynin Chloride | 15 | $401 | $27 |
| Ciprofloxacin | 67 | $331 | $5 |
| Sulfamethoxazole-Trimethoprim | 15 | $77 | $5 |
Money from drug and device companies
$3,021 in 2025
| 2025 | 19 | 85 | None | $3,021 |
| 2024 | 17 | 37 | None | $1,890 |
| 2023 | 24 | 85 | None | $2,927 |
| 2022 | 23 | 91 | None | $3,173 |
| 2021 | 25 | 51 | None | $1,637 |
| 2020 | 15 | 36 | None | $917 |
| 2019 | 22 | 94 | None | $1,995 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sumitomo Pharma America | Gemtesa | $874 | 34 payments
|
| AngioDynamics | Nanoknife | $534 | 2 payments
|
| Ferring Pharmaceuticals | Adstiladrin | $263 | 7 payments
|
| Abbvie | Botox | $196 | 7 payments
|
| Coloplast | Titan | $196 | 2 payments
|
| Procept Biorobotics | Aquabeam Robotic System | $187 | 3 payments
|
See all 85 published payments
| Abbvie | Meals · 2025-12-19 | Botox | $28 |
| Sumitomo Pharma America | Meals · 2025-12-18 | Gemtesa | $34 |
| Sumitomo Pharma America | Meals · 2025-12-04 | Gemtesa | $39 |
| AngioDynamics | Travel · 2025-12-02 | Nanoknife | $60 |
| Coloplast | Meals · 2025-12-02 | Titan | $172 |
| AngioDynamics | Travel · 2025-12-01 | Nanoknife | $474 |
| Novartis Pharmaceuticals | Meals · 2025-11-21 | Pluvicto | $34 |
| Progenics Pharmaceuticals | Meals · 2025-11-18 | Pylarify | $27 |
| Blue Earth Diagnostics | Meals · 2025-11-14 | Posluma | $37 |
| Sumitomo Pharma America | Meals · 2025-11-13 | Gemtesa | $10 |
| Abbvie | Meals · 2025-11-13 | Botox | $23 |
| Ferring Pharmaceuticals | Meals · 2025-11-13 | Adstiladrin | $21 |
| Sumitomo Pharma America | Meals · 2025-11-07 | Gemtesa | $34 |
| Astellas Pharma US | Meals · 2025-11-05 | Padcev | $115 |
| Pfizer | Meals · 2025-10-30 | Xtandi | $31 |
| Astellas Pharma US | Meals · 2025-10-30 | Xtandi | $1 |
| Coloplast | Meals · 2025-10-29 | Titan | $24 |
| Astellas Pharma US | Meals · 2025-10-29 | Xtandi | $3 |
| Blue Earth Diagnostics | Meals · 2025-10-24 | Posluma | $39 |
| Ferring Pharmaceuticals | Meals · 2025-10-23 | Adstiladrin | $19 |
| Sumitomo Pharma America | Meals · 2025-10-22 | Gemtesa | $39 |
| Verity Pharmaceuticals | Meals · 2025-10-16 | Trelstar | $18 |
| Sumitomo Pharma America | Meals · 2025-10-09 | Gemtesa | $5 |
| Sumitomo Pharma America | Meals · 2025-10-09 | Gemtesa | $5 |
| Procept Biorobotics | Meals · 2025-09-30 | Aquabeam Robotic System | $27 |
| Dendreon Pharmaceuticals | Meals · 2025-09-12 | Provenge | $26 |
| Sumitomo Pharma America | Meals · 2025-09-09 | Gemtesa | $9 |
| Sumitomo Pharma America | Meals · 2025-08-18 | Gemtesa | $32 |
| Astellas Pharma US | Meals · 2025-08-12 | Xtandi | $26 |
| Sumitomo Pharma America | Meals · 2025-08-06 | Orgovyx | $24 |
| Dendreon Pharmaceuticals | Meals · 2025-08-05 | Provenge | $16 |
| Abbvie | Meals · 2025-08-01 | Botox | $28 |
| Sumitomo Pharma America | Meals · 2025-07-29 | Gemtesa | $34 |
| Verity Pharmaceuticals | Meals · 2025-07-15 | Trelstar | $16 |
| Progenics Pharmaceuticals | Meals · 2025-07-10 | Pylarify | $22 |
| Sumitomo Pharma America | Meals · 2025-07-08 | Orgovyx | $26 |
| Sumitomo Pharma America | Meals · 2025-07-08 | Gemtesa | $39 |
| Sumitomo Pharma America | Meals · 2025-06-26 | Gemtesa | $20 |
| Sumitomo Pharma America | Meals · 2025-06-25 | Gemtesa | $20 |
| Astellas Pharma US | Meals · 2025-06-21 | Xtandi | $5 |
| Sumitomo Pharma America | Meals · 2025-06-20 | Gemtesa | $29 |
| Pfizer | Meals · 2025-06-20 | Xtandi | $24 |
| Ferring Pharmaceuticals | Meals · 2025-06-13 | Adstiladrin | $27 |
| Sumitomo Pharma America | Meals · 2025-06-05 | Gemtesa | $23 |
| Accord Healthcare | Meals · 2025-06-04 | Camcevi | $24 |
| Sumitomo Pharma America | Meals · 2025-06-02 | Gemtesa | $38 |
| Sumitomo Pharma America | Meals · 2025-05-30 | Orgovyx | $23 |
| Verity Pharmaceuticals | Meals · 2025-05-30 | Tlando | $18 |
| Progenics Pharmaceuticals | Meals · 2025-05-29 | Pylarify | $24 |
| Dendreon Pharmaceuticals | Meals · 2025-05-22 | Provenge | $19 |
| Sumitomo Pharma America | Meals · 2025-05-21 | Gemtesa | $21 |
| Abbvie | Meals · 2025-05-21 | Botox | $27 |
| Endo USA | Meals · 2025-05-14 | Xiaflex | $28 |
| Astellas Pharma US | Meals · 2025-05-09 | Xtandi | $3 |
| Sumitomo Pharma America | Meals · 2025-05-08 | Gemtesa | $41 |
| Sumitomo Pharma America | Meals · 2025-05-08 | Gemtesa | $39 |
| Astellas Pharma US | Meals · 2025-05-08 | Xtandi | $24 |
| Sumitomo Pharma America | Meals · 2025-05-07 | Gemtesa | $35 |
| Ferring Pharmaceuticals | Meals · 2025-05-02 | Adstiladrin | $29 |
| Sumitomo Pharma America | Meals · 2025-05-01 | Gemtesa | $38 |
| Procept Biorobotics | Meals · 2025-04-26 | Aquabeam Robotic System | $149 |
| Abbvie | Meals · 2025-04-25 | Botox | $29 |
| Sumitomo Pharma America | Meals · 2025-04-24 | Gemtesa | $9 |
| Merck Sharp & Dohme | Meals · 2025-04-23 | Keytruda | $33 |
| Ferring Pharmaceuticals | Meals · 2025-04-23 | Adstiladrin | $116 |
| Bluewind Medical | Meals · 2025-04-18 | Revi | $26 |
| Progenics Pharmaceuticals | Meals · 2025-04-15 | Pylarify | $24 |
| Sumitomo Pharma America | Meals · 2025-04-09 | Gemtesa | $12 |
| Pfizer | Meals · 2025-03-28 | Xtandi | $26 |
| Myriad Genetic Laboratories | Meals · 2025-03-26 | Myrisk | $25 |
| Sumitomo Pharma America | Meals · 2025-03-20 | Gemtesa | $11 |
| Merck Sharp & Dohme | Meals · 2025-03-20 | Keytruda | $34 |
| Procept Biorobotics | Meals · 2025-03-19 | Aquabeam Robotic System | $11 |
| Ferring Pharmaceuticals | Meals · 2025-03-14 | Adstiladrin | $21 |
| Sumitomo Pharma America | Meals · 2025-03-12 | Gemtesa | $14 |
| Immunitybio | Meals · 2025-03-07 | Anktiva | $23 |
| Sumitomo Pharma America | Education · 2025-03-06 | Gemtesa | $5 |
| Sumitomo Pharma America | Meals · 2025-03-06 | Gemtesa | $37 |
| Sumitomo Pharma America | Meals · 2025-03-03 | Gemtesa | $34 |
| Abbvie | Meals · 2025-02-28 | Botox | $31 |
| Sumitomo Pharma America | Meals · 2025-02-21 | Gemtesa | $18 |
| Ferring Pharmaceuticals | Meals · 2025-02-07 | Adstiladrin | $29 |
| Sumitomo Pharma America | Meals · 2025-02-06 | Gemtesa | $35 |
| Sumitomo Pharma America | Meals · 2025-02-05 | Gemtesa | $41 |
| Abbvie | Meals · 2025-01-10 | Botox | $32 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,890
| Edap Technomed | None | $690 | 3 payments
|
| Dendreon Pharmaceuticals | Provenge | $435 | 4 payments
|
| Sumitomo Pharma America | Gemtesa | $351 | 12 payments
|
| Astellas Pharma US | Myrbetriq | $89 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $44 | 2 payments
|
| Bluewind Medical | Revi | $39 | 2 payments
|
| Immunitybio | Anktiva | $34 | 1 payment
|
| Urogen Pharma | Jelmyto | $26 | 1 payment
|
| Axonics | Axonics | $24 | 1 payment
|
| Abbvie | Lupron Depot | $23 | 1 payment
|
| Accord Healthcare | Camcevi | $23 | 1 payment
|
| Medtronic | Interstim | $21 | 1 payment
|
| Ferring Pharmaceuticals | Adstiladrin | $20 | 1 payment
|
| Janssen Biotech | Erleada | $20 | 1 payment
|
| Coloplast | Titan | $19 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $17 | 1 payment
|
| Biotissue Holdings | None | $15 | 1 payment
|
2023: $2,927
| Sumitomo Pharma America | Gemtesa | $693 | 25 payments
|
| AngioDynamics | Nanoknife | $594 | 4 payments
|
| Edap Technomed | None | $311 | 2 payments
|
| Astellas Pharma US | Myrbetriq | $248 | 10 payments
|
| Agiliti Surgical | Sonablate | $151 | 2 payments
|
| Janssen Biotech | Erleada | $135 | 6 payments
|
| Pfizer | Xtandi | $90 | 6 payments
|
| UroGen Pharma | Jelmyto | $84 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $72 | 2 payments
|
| Myriad Genetic Laboratories | Myrisk | $64 | 3 payments
|
| Abbvie | Lupron Depot | $62 | 3 payments
|
| Amgen | Xgeva | $59 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $56 | 3 payments
|
| Dendreon Pharmaceuticals | Provenge | $48 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $39 | 2 payments
|
| Biotissue Holdings | Neox | $38 | 2 payments
|
| Accord Healthcare | Camcevi | $35 | 1 payment
|
| Boston Scientific | Lithovue | $31 | 1 payment
|
| Coloplast | Titan | $28 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $23 | 1 payment
|
| Medtronic | Interstim | $20 | 1 payment
|
| Smith+Nephew | Stravix | $18 | 1 payment
|
| C. R. Bard Inc. & Subsidiaries | Bard Urinary Drainage Bag | $17 | 1 payment
|
| Mayne Pharma Commercial | None | $11 | 2 payments
|
2022: $3,173
| Teleflex | Urolift | $1,204 | 6 payments
|
| Urovant Sciences | Gemtesa | $536 | 22 payments
|
| Antares Pharma | Nocdurna | $308 | 15 payments
|
| Astellas Pharma US | Myrbetriq | $220 | 7 payments
|
| Dendreon Pharmaceuticals | Provenge | $213 | 7 payments
|
| Abbvie | Lupron Depot | $194 | 8 payments
|
| AngioDynamics | Nanoknife | $72 | 3 payments
|
| Myovant Sciences | Orgovyx | $70 | 3 payments
|
| Hollister | Infyna Chic | $43 | 2 payments
|
| Amgen | Prolia | $38 | 1 payment
|
| Janssen Biotech | Erleada | $36 | 2 payments
|
| Coloplast | Titan | $36 | 2 payments
|
| Boston Scientific | General - Kidney Stone Disease | $29 | 1 payment
|
| Olympus America | Itind System | $23 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $22 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $20 | 1 payment
|
| Myriad Genetic Laboratories | Prolaris | $20 | 1 payment
|
| Pfizer | Xtandi | $18 | 1 payment
|
| Profound Medical | Tulsa-Pro | $16 | 1 payment
|
| SRS Medical Systems | Urocuff | $15 | 1 payment
|
| Allergan | Botox | $14 | 1 payment
|
| Endo Pharmaceuticals | Xiaflex | $14 | 1 payment
|
| UroGen Pharma | Jelmyto | $12 | 1 payment
|
2021: $1,637
| Teleflex | Urolift System | $473 | 2 payments
|
| Astellas Pharma US | Xtandi | $196 | 5 payments
|
| Myovant Sciences | Orgovyx | $122 | 5 payments
|
| Antares Pharma | Xyosted | $107 | 6 payments
|
| AbbVie | Lupron Depot | $76 | 3 payments
|
| PROCEPT BioRobotics | Aquabeam Robotic System | $75 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $75 | 1 payment
|
| Coloplast | Titan | $74 | 4 payments
|
| Urovant Sciences | Gemtesa | $65 | 3 payments
|
| Janssen Biotech | Erleada | $62 | 4 payments
|
| Merck Sharp & Dohme | Keytruda | $47 | 2 payments
|
| Myriad Genetic Laboratories | Prolaris | $37 | 2 payments
|
| Amgen | Prolia | $25 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $23 | 1 payment
|
| 180 Medical | None | $22 | 1 payment
|
| TherapeuticsMD | Imvexxy | $20 | 1 payment
|
| Hollister | Infyna Chic | $20 | 1 payment
|
| Pfizer | Xtandi | $18 | 1 payment
|
| Allergan | Botox | $16 | 1 payment
|
| Clarus Therapeutics | Jatenzo | $16 | 1 payment
|
| Blue Earth Diagnostics | Axumin | $16 | 1 payment
|
| Photocure | Cysview | $15 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $13 | 1 payment
|
| Axonics | Axonics R-Snm System | $12 | 1 payment
|
| Laborie Medical Technologies | None | $12 | 1 payment
|
2020: $917
| NeoTract | Urolift | $328 | 4 payments
|
| 180 Medical | Gentlecath | $100 | 6 payments
|
| Pfizer | Xtandi | $88 | 5 payments
|
| Astellas Pharma US | Xtandi | $78 | 4 payments
|
| AbbVie | Lupron Depot | $46 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $42 | 2 payments
|
| Travere Therapeutics | (815) Thiola | $40 | 2 payments
|
| Boston Scientific | General - Bph | $38 | 2 payments
|
| Coloplast | Penile & Testicular Reconstructn | $35 | 2 payments
|
| Janssen Biotech | Erleada | $30 | 2 payments
|
| Amgen | Prolia | $24 | 1 payment
|
| Dentsply Ih | Lofric | $21 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $17 | 1 payment
|
| Celgene | Revlimid | $17 | 1 payment
|
| Laborie Medical Technologies | None | $13 | 1 payment
|
2019: $1,995
| Boston Scientific | General Therapies | $365 | 8 payments
|
| NeoTract | Urolift | $199 | 2 payments
|
| Janssen Biotech | Erleada | $183 | 15 payments
|
| Pfizer | Xtandi | $178 | 13 payments
|
| Astellas Pharma US | Xtandi | $161 | 17 payments
|
| Amgen | Xgeva | $117 | 4 payments
|
| Dendreon Pharmaceuticals | Provenge | $112 | 4 payments
|
| Ferring Pharmaceuticals | Nocdurna | $107 | 5 payments
|
| C. R. Bard Inc. & Subsidiaries | None | $92 | 2 payments
|
| 180 Medical | Gentlecath | $84 | 4 payments
|
| TherapeuticsMD | Imvexxy | $64 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Xofigo | $56 | 3 payments
|
| Retrophin | (815) Thiola | $51 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | None | $51 | 2 payments
|
| Endo Pharmaceuticals | Aveed | $44 | 2 payments
|
| AbbVie | Lupron Depot | $35 | 2 payments
|
| Rigel Pharmaceuticals | Tavalisse | $25 | 1 payment
|
| Celgene | Revlimid | $18 | 1 payment
|
| Antares Pharma | Xyosted | $17 | 1 payment
|
| Dornier MedTech America | Lithotripters & Accessories | $16 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $15 | 1 payment
|
| PROCEPT BioRobotics | Aquabeam Robotic System | $5 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1023067329
- Licence
- CA A67706California A67706: Current · expires 2028-08-31
- Trained
- Northwestern University Feinberg Medical School, 1997
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 2495 Hospital Dr Ste 425, Mountain View, CA, 94040
- NPI first listed
- 2006-05-06
- NPI last updated
- 2025-12-29
- NPI record certified
- 2025-12-29
This is when the NPI record was last certified, not a medical board exam.